Core Insights - U.S. President Donald Trump has threatened to increase tariffs on South Korean imports from 15% to 25%, citing the South Korean National Assembly's failure to ratify a "Historic Trade Agreement" [1][2] Impact on Industries and Companies - The proposed tariff hike targets key sectors of the South Korean economy, specifically automobiles, pharmaceuticals, and lumber, along with other "reciprocal" goods [5] - The automotive industry, which constitutes 27% of South Korea's exports to the U.S., will be significantly impacted, with Hyundai Motor Co. and Kia Corp. being the most exposed [6][7] - Major pharmaceutical companies like Samsung Biologics and Celltrion are also at risk, as their direct exports of biosimilars could be affected by the tariffs [8] - South Korean semiconductor manufacturers, including Samsung Electronics and SK Hynix, are on alert due to the broader "reciprocal" tariff policy, although the impact may be limited [9] Long-Term Outlook for South Korean ETFs - Despite immediate volatility, the long-term outlook for South Korean ETFs is supported by the South Korean government's efforts to address tariff threats through diplomacy and proposed legislation for a $350 billion investment in the U.S. [10][11] - South Korea's diversified export base and strong balance sheets of leading conglomerates provide a more constructive view for the future [12] - The restoration of the 15% tariff cap is anticipated once the National Assembly clarifies the investment timeline, presenting a potential recovery opportunity for investors [13] ETFs to Watch - **iShares MSCI South Korea ETF (EWY)**: Net assets of $11.24 billion, top holdings include Samsung Electronics (26.48%), SK Hynix (18.37%), and Hyundai Motors (3.11%), with a 116.1% increase over the past year [14][15] - **Franklin FTSE South Korea ETF (FLKR)**: Net assets of $316.2 million, top holdings include Samsung Electronics (20.26%), SK Hynix (18.75%), and Hyundai Motors (3.13%), with a 106.5% increase over the past year [16] - **Matthews Korea Active ETF (MKOR)**: Active fund with net assets of $85.9 million, top holdings include Samsung Electronics (24.9%), SK Square (4.6%), and SK Hynix (4.4%), with an 87.5% increase over the past year [17][18]

Recently IND-Cleared HER2 × CD3 T-Cell Engager Highlighted by Global Biopharmaceutical PartnerBURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced that its lead multispecific antibody oncology program, ABP-102 / CT-P72, was featured in a presentation by its global collaboration partner, Celltrion, at the 2026 J.P. Morgan Healthcare Conference. Celltrio ...

BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced that its lead multispecific antibody oncology program, ABP-102 / CT-P72, was featured in a presentation by its global collaboration partner, Celltrion, at the 2026 J.P. Morgan Healthcare Conference. Celltrion’s senior executives attended the conference to present the company’s latest progress in new ...

此外，其母亲、龙美术馆荣誉馆长洪罗喜近期向他赠予的 181 万股三星物产股票，也进一步拉高了其持股总价值。 李在镕持股价值的大幅攀升，与韩国股市的整体估值上调进程同步。韩国综合股价指数于去年年底首次突破 4000 点关口，自 2025 年 6 月李在明总统就职以 来，在半导体行业引领的复苏浪潮，以及政府通过公司治理改革、股东回报优化以缩小"韩国折价"的政策推动下，该指数累计涨幅已超 50%。 该研究院还表示，截至 2026 年初，韩国 45 家大型企业集团控股股东的持股总价值达到 93.34 万亿韩元（现汇率约合 4520.46 亿元人民币），较一年前的 57.88 万亿韩元增长 61.3%。此次统计的对象为韩国公平交易委员会分类标准下，个人持股价值超 1000 亿韩元（现汇率约合 4.84 亿元人民币）的企业集团 负责人。 在持股价值总排名中，Celltrion 创始人徐廷珍以 13.69 万亿韩元（现汇率约合 663.01 亿元人民币）的持股价值稳居第二；Kakao 创始人金范洙的持股价值从 3.95 万亿韩元增至 6.55 万亿韩元（现汇率约合 317.22 亿元人民币），增幅达 61.5%，排名也从第 ...

格隆汇1月2日｜2026年第一个交易日，韩股大涨。韩国综合指数盘中一度涨超2%报4313.55点，再创历史新高；最终收涨2.27%报4309.63点，创收盘历史新 高。受人工智能驱动需求持续增长的乐观情绪提振，权重半导体股纷纷走高。三星电子和SK海力士领涨，三星电子收涨7.17%创2024年11月15日以来最大单 日涨幅。市场预期全球芯片行业的上升周期将继续支撑今年的盈利增长。 韩国2025年出口额预计将达到创纪录的7097亿美元，半导体出货量也创历史新高，同时韩国录得2017年以来最大的贸易顺差，这些强劲的宏观经济信号进一 步提振了市场情绪。 2025年韩国综合指数上涨76%，创下1999年以来最大年度涨幅。三星、SK海力士和Celltrion是该指数涨幅最大的个股。 ...

Market Overview - Asian assets experienced a significant surge at the beginning of 2026, with the offshore and onshore RMB both breaking the 6.97 mark against the USD, reaching the highest level since May 2023 [4] - The Hang Seng Index opened high on the first trading day of the year, rising nearly 1.8%, while the Hang Seng Tech Index increased by 3.4% [1] Company Performance - Baidu Group saw a notable increase of over 8.5%, surpassing last year's high, following the announcement of plans to spin off Kunlun Chip for a Hong Kong listing [1] - Other notable performers included Li Auto, which rose nearly 7%, and NIO and Leap Motor, both increasing by over 1% [1] - NetEase and Tencent also experienced gains, with NetEase up over 5% and Tencent up over 3% [1] Stock Highlights - The following companies showed significant stock performance: - Baidu Group-SW: Current price 142.700, up 8.52% [2] - Li Auto-W: Current price 69.350, up 6.94% [2] - NetEase-S: Current price 226.000, up 5.31% [2] - BYD Electronics: Current price 35.100, up 4.34% [2] - Semiconductor Manufacturing International Corporation: Current price 74.500, up 4.27% [2] New Listings - The newly listed company, Biren Technology, saw its stock surge by 110% after revealing significant revenue growth from 62 million yuan in 2023 to 337 million yuan in 2024, with a backlog of 822 million yuan in orders [2] Global Market Trends - The KOSPI index in South Korea opened higher, with Samsung Electronics reaching a historical high, increasing by 3.2% [3] - The biopharmaceutical company Celltrion's stock rose by 10% following a $473 million manufacturing agreement with Eli Lilly [3] Precious Metals - Precious metals experienced a collective rise, with spot gold increasing by 0.7% and achieving a 64% increase for the entire year of 2025, marking the largest annual gain since 1979 [7] - Spot silver rose by 1.8%, reaching a historical high of $83.62, with a 147% increase in 2025, the largest recorded annual gain [7] - Platinum and palladium both rose by 1.6%, with platinum reaching a historical high and annual gains of 127%, while palladium saw a 76% increase, the best in 15 years [7] Investment Sentiment - There is a growing interest from overseas "long money" in Chinese assets, with a notable shift towards technology and biotechnology sectors [7] - Major financial institutions like Goldman Sachs, UBS, and JPMorgan predict a sustained rebound for Chinese assets in 2026, driven by profit growth, accelerated innovation, and attractive valuations [7]

Group 1 - Asian assets experienced a significant surge at the beginning of 2026, with the Renminbi breaking the 6.97 mark against the US dollar, reaching its highest level since May 2023 [3] - The Hang Seng Index opened high on the first trading day of the year, rising nearly 1.8%, while the Hang Seng Tech Index increased by 3.4%, driven by strong performances from companies like Baidu, which rose over 8.5% [1] - New energy vehicle companies saw a broad increase, with Li Auto rising nearly 7% and NIO and Leap Motor both gaining over 1% [1] Group 2 - The stock of Wall Street's new company, Bilan Technology, surged by 110% after announcing significant revenue growth from 62 million yuan in 2023 to 337 million yuan in 2024, with a backlog of orders worth 822 million yuan [2] - Samsung Electronics' stock reached a historical high, increasing by 3.2%, as the CEO highlighted the competitive edge of their HBM4 technology [2] - The KOSPI index in South Korea also opened higher, reflecting positive market sentiment [2] Group 3 - Precious metals saw a collective rise, with spot gold increasing by 0.7% and achieving a remarkable annual gain of 64% in 2025, the largest since 1979 [7] - Spot silver rose by 1.8%, reaching a historical high of $83.62, with a staggering annual increase of 147% in 2025 [7] - Platinum and palladium both rose by 1.6%, with platinum hitting a historical peak and achieving a 127% annual increase, while palladium recorded a 76% gain, marking its best performance in 15 years [8] Group 4 - The FTSE China A50 index futures surged past the 15,360 mark, gaining over 0.5% during the trading session [5] - Overseas "long money" is actively positioning in Chinese assets, with a notable increase in interest towards the Chinese stock market, particularly in technology and biotechnology sectors [9] - Major financial institutions like Goldman Sachs, UBS, and JPMorgan predict a sustained rebound for Chinese assets in 2026, driven by profit growth, accelerated innovation, and attractive valuations [9]

Market Overview - Asian assets experienced a significant surge at the beginning of 2026, with the Renminbi breaking the 6.97 mark against the US dollar, reaching a new high since May 2023 [1][2] - The Hang Seng Index opened high on the first trading day of the year, rising nearly 1.8%, while the Hang Seng Tech Index increased by 3.4% [1] Company Highlights - Baidu Group saw a notable increase of over 8.5%, reaching a new high after announcing plans to spin off Kunlun Chip for a Hong Kong listing [1] - Other companies in the new energy vehicle sector, such as Li Auto, NIO, and Leap Motor, also experienced gains, with Li Auto rising nearly 7% [1] - NetEase increased by over 5%, while Alibaba and Tencent both rose approximately 3% [1] Stock Performance - Baidu Group's stock price reached 142.70, with a rise of 11.20, reflecting an 8.52% increase [2] - Li Auto's stock price was 69.35, up by 4.50, or 6.94% [2] - New stock Biran Technology saw a dramatic increase of 110% after its hearing materials indicated a revenue growth from 62 million yuan in 2023 to 337 million yuan in 2024, with a backlog of 822 million yuan in orders [2] Currency and Commodity Trends - The offshore and onshore Renminbi both surpassed the 6.97 mark against the US dollar, marking a significant appreciation [3] - Precious metals saw a collective rise, with spot gold increasing by 0.7% and silver by 1.8%, with silver reaching a historical high of $83.62 [5] - Platinum and palladium both rose by 1.6%, with platinum achieving a 127% increase in 2025, the highest in 15 years for palladium [5] Institutional Insights - There is a growing interest from overseas investors in Chinese assets, particularly in technology and biotechnology sectors [6] - Major financial institutions like Goldman Sachs, UBS, and JPMorgan predict a sustained rebound for Chinese assets in 2026, driven by profit growth, accelerated innovation, and attractive valuations [6]

Core Viewpoint - Celltrion expects its annual operating profit to exceed 1 trillion KRW (approximately 693 million USD) for the first time this year, driven by strong sales of high-end products [1][3]. Group 1: Financial Projections - The company forecasts that its operating profit will more than double from last year's 492 billion KRW to 1.16 trillion KRW by 2025, with sales projected to increase from 3.56 trillion KRW in 2024 to 4.11 trillion KRW [1][3]. - For the fourth quarter of this year, Celltrion anticipates an operating profit of 472.2 billion KRW and sales of 1.28 trillion KRW [1][3]. Group 2: Product Performance - The global sales growth of flagship biosimilars, including Remsima SC, Yuflyma, and Vegzelma, continues to boost annual profits [1][3]. - Biosimilars such as Remsima SC, Steqeyma, Yuflyma, and Vegzelma are expected to achieve double-digit sales growth globally, accounting for 60% of total sales [1][3]. Group 3: Strategic Focus - To maintain growth, the company will focus on promoting high-margin products while reducing the share of products with high raw material costs [2][4]. - Celltrion plans to launch contract manufacturing organization (CMO) products for Eli Lilly and introduce its own biosimilar products to the U.S. market through its New Jersey facility [2][4].

Amneal Pharmaceuticals FY Conference Summary Company Overview - **Company**: Amneal Pharmaceuticals (NasdaqGS:AMRX) - **Date**: December 03, 2025 - **Context**: Discussion at the 37th Annual Piper Sandler Healthcare Conference Key Points Industry and Business Evolution - Amneal has undergone a significant financial turnaround over the past six years, diversifying its business and reducing debt, leading to its best operational state in years [2][4] - The company has shifted focus from oral solid generics to more complex generics, injectables, and biosimilars, which are less exposed to price erosion [3][4] Affordable Medicines Segment - The affordable medicines business generates approximately $1.5 billion in revenue, growing at mid- to high-single digits [3] - Oral solids revenue contribution has decreased from 53% to about 25% over the past few years, with expectations to drop to 10%-15% in the future [3][4] - 65% of ANDAs pending at the FDA are in complex generics, with 90% of the R&D pipeline focused on this area [4] Generic Injectables - Annual revenue from generic injectables has grown from $130 million to an expected $200 million this year, with projections of $240-$250 million next year [7] - The company has about 40 products in the generic injectables space and plans to add approximately 10 new products annually [7] - Notable upcoming product launches include Risperidone, IXO, and Lanreotide [7] Biosimilars - Amneal has transitioned into biosimilars, generating about $100 million in revenue this year with three products launched [11] - The company anticipates launching five new biosimilars by 2028, with a significant opportunity in the generic Xolair market, valued at $4 billion and growing at 30% annually [12][14] - The company expects to be the second generic in the market for Xolair, which could yield hundreds of millions in revenue [16] Specialty Products - Crexont, a new product for Parkinson's patients, is expected to generate $60 million in revenue this year, with projections of $120 million next year [23][24] - The product is priced between $3,000 and $5,000 annually, significantly lower than competitors like AbbVie's Vyalev [28][29] - The company is conducting a phase four study to demonstrate Crexont's effectiveness, with results expected to enhance its market position [25] Partnerships and Future Outlook - Amneal has partnered with Pfizer regarding the Metsera pipeline, with plans to build two new manufacturing sites in India [36][37] - The company is exploring opportunities in the GLP-1 market, focusing on complex peptides and manufacturing capabilities for future generics [42] Financial Metrics - The overall gross margin for Amneal is approximately 44%, with injectables achieving around 50% margins and potential for biosimilars like Xolair to reach 80% [20][22] - Current EBITDA stands at about 22%, with potential to exceed 30% if the company captures full margins from its products [22] Additional Insights - The company emphasizes organic growth and selective M&A, with a focus on building a sustainable business model over the next 10-20 years [19] - Amneal's strategy includes minimizing exposure to price erosion by focusing on less competitive segments of the market [4][5]